Relapse risk by DI group in MEMS subcohort stratified by adherence
| Characteristics . | MEMS subcohort (adherence ≥85%) . | MEMS subcohort (adherence <85%) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate HR (95% CI) . | P value . | Multivariable HR (95% CI) . | P value . | Univariate HR (95% CI) . | P value . | Multivariable HR (95% CI) . | P value . | |
| DI (reference: normal DI) | ||||||||
| High DI | 2.2 (1.0-4.7) | .04 | 2.4 (1.0-5.5) | .04 | 0.7 (0.2-2.2) | .5 | 0.9 (0.2-3.8) | .9 |
| Age | ||||||||
| Per year increase | 1.1 (1.0-1.2) | .006 | 1.1 (1.0-1.1) | .8 | 1.0 (0.9-1.1) | .9 | — | — |
| Sex (reference: female) | ||||||||
| Male | 1.0 (0.5-2.2) | .9 | — | — | 1.7 (0.5-6.0) | .4 | — | — |
| Race/ethnicity (reference: non-Hispanic White) | ||||||||
| Asian | 1.1 (0.3-3.7) | .9 | — | — | — | — | — | — |
| African American or Black | 0.4 (0.1-3.0) | .4 | — | — | 1.0 (0.2-4.9) | .9 | — | — |
| Hispanic | 2.1 (0.9-4.9) | .1 | — | — | 0.6 (0.1-3.1) | .5 | — | — |
| NCI risk group (reference: standard risk) | ||||||||
| High risk | 1.9 (0.9-3.9) | .1 | — | — | 2.0 (0.6-6.5) | .2 | — | — |
| Cytogenetics (reference: neutral) | ||||||||
| Favorable | 0.2 (0.1-0.6) | .005 | 0.3 (0.1-0.8) | .02 | 1.0 (0.2-3.8) | .9 | 0.9 (0.2-4.0) | .9 |
| Unfavorable | 1.0 (0.2-4.3) | .9 | 0.7 (0.2-3.2) | .7 | 24.8 (3.8-160.5) | .0008 | 21.4 (2.9-160.4) | .003 |
| Time from start of maintenance | ||||||||
| Per year increase | 0.4 (0.1-1.1) | .08 | 0.2 (0.1-0.8) | .02 | 0.4 (0.1-2.1) | .3 | — | — |
| Treatment interruptions during months 1-4 (reference: no) | ||||||||
| Yes | 1.3 (0.6-2.7) | .5 | 1.2 (0.5-2.7) | .7 | 0.5 (0.1-1.9) | .3 | 0.8 (0.2-3.0) | .7 |
| Adherence | ||||||||
| Per unit increase | 0.9 (0.8-1.0) | .01 | 0.9 (0.8-1.1) | .07 | 1.0 (0.9-1.0) | .7 | — | — |
| Characteristics . | MEMS subcohort (adherence ≥85%) . | MEMS subcohort (adherence <85%) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate HR (95% CI) . | P value . | Multivariable HR (95% CI) . | P value . | Univariate HR (95% CI) . | P value . | Multivariable HR (95% CI) . | P value . | |
| DI (reference: normal DI) | ||||||||
| High DI | 2.2 (1.0-4.7) | .04 | 2.4 (1.0-5.5) | .04 | 0.7 (0.2-2.2) | .5 | 0.9 (0.2-3.8) | .9 |
| Age | ||||||||
| Per year increase | 1.1 (1.0-1.2) | .006 | 1.1 (1.0-1.1) | .8 | 1.0 (0.9-1.1) | .9 | — | — |
| Sex (reference: female) | ||||||||
| Male | 1.0 (0.5-2.2) | .9 | — | — | 1.7 (0.5-6.0) | .4 | — | — |
| Race/ethnicity (reference: non-Hispanic White) | ||||||||
| Asian | 1.1 (0.3-3.7) | .9 | — | — | — | — | — | — |
| African American or Black | 0.4 (0.1-3.0) | .4 | — | — | 1.0 (0.2-4.9) | .9 | — | — |
| Hispanic | 2.1 (0.9-4.9) | .1 | — | — | 0.6 (0.1-3.1) | .5 | — | — |
| NCI risk group (reference: standard risk) | ||||||||
| High risk | 1.9 (0.9-3.9) | .1 | — | — | 2.0 (0.6-6.5) | .2 | — | — |
| Cytogenetics (reference: neutral) | ||||||||
| Favorable | 0.2 (0.1-0.6) | .005 | 0.3 (0.1-0.8) | .02 | 1.0 (0.2-3.8) | .9 | 0.9 (0.2-4.0) | .9 |
| Unfavorable | 1.0 (0.2-4.3) | .9 | 0.7 (0.2-3.2) | .7 | 24.8 (3.8-160.5) | .0008 | 21.4 (2.9-160.4) | .003 |
| Time from start of maintenance | ||||||||
| Per year increase | 0.4 (0.1-1.1) | .08 | 0.2 (0.1-0.8) | .02 | 0.4 (0.1-2.1) | .3 | — | — |
| Treatment interruptions during months 1-4 (reference: no) | ||||||||
| Yes | 1.3 (0.6-2.7) | .5 | 1.2 (0.5-2.7) | .7 | 0.5 (0.1-1.9) | .3 | 0.8 (0.2-3.0) | .7 |
| Adherence | ||||||||
| Per unit increase | 0.9 (0.8-1.0) | .01 | 0.9 (0.8-1.1) | .07 | 1.0 (0.9-1.0) | .7 | — | — |
Multivariable models adjust for covariates with P < .1 on univariate comparison, except treatment interruptions, which were retained in final models. Favorable cytogenetics included t(12;21); hyperdiploidy; trisomy 4 and 10; or trisomy 4, 10, and 17. Unfavorable cytogenetics included t(9;22), t(4;11), hypodiploidy, or extreme hypodiploidy. Neutral cytogenetics implied absence of favorable or unfavorable cytogenetics.
—, indicates variables that were not adjusted for in multivariable models; HR, hazard ratio.